• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Diabetes Control from 1999 to 2018: Better, then Worse?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Fang et al. (NEJM, 2021) assessed national diabetes trends in the US including glycemic control, treatment and population subgroups most likely to have untreated risk factors

METHODS:

  • Cross-sectional analysis of data
  • Participants
    • US adults with diabetes participating in the National Health and Nutrition Examination Survey (NHANES)
  • Study design
    • Glycemic control: Glycated hemoglobin level <7%
    • Lipid control: Non–high-density lipoprotein cholesterol level <130 mg per deciliter
    • Blood pressure control: <140/90 mm Hg
    • The authors analyzed data from 1999 through 2018

RESULTS:

Diabetes control improved from 1999 to the early 2010s, but later stalled and declined

  • The number of adults who achieved glycemic control declined between the 2007-2010 period and the 2015-2018 period
    • 2007 to 2010: 57.4% (95% CI, 52.9 to 61.8)
    • 2015 to 2018: 50.5% (95% CI, 45.8 to 55.3)
  • While there were major improvements in lipid control in the early 2000s, there was little improvement between 2007 to 2010 and 2015 to 2018
    • 2007 to 2010: 52.3% (95% CI, 49.2 to 55.3)
    • 2015 to 2018: 55.7% (95% CI, 50.8 to 60.5)
  • The percentage of adults with good blood pressure control decreased between 2011 to 2014 and 2015 to 2018
    • 2011 to 2014: 74.2% (95% CI, 70.7 to 77.4)
    • 2015 to 2018: 70.4% (95% CI, 66.7 to 73.8)
  • The percentage of participants in whom all three targets were simultaneously achieved plateaued after 2010
    • 2015 to 2018: 22.2% (95% CI, 17.9 to 27.3)
  • Treatment trends
    • Use of glucose-lowering medication or any blood-pressure–lowering medication were unchanged after 2010
    • Use of statins plateaued after 2014
    • Use of combination therapy
      • Declined in those with uncontrolled blood pressure
      • Plateaued for those with poor glycemic control
  • Population data
    • The following groups were less likely to receive treatment when targets were not achieved
      • Younger adults | Mexican Americans | Those without health insurance
    • Non-Hispanic Blacks compared to non-Hispanic Whites were
      • Less likely than to receive combination therapy when glycemic targets were not achieved
      • More likely to receive combination therapy when blood-pressure targets were not met

CONCLUSION:

  • Despite a decade (1999 to 2010) of significant progress in controlling diabetes, adult NHANES participants have worse glycemic and blood-pressure control, and lipid control has leveled off
  • The authors state

After steady declines from 1995 to 2010, rates of hyperglycemic emergencies and amputations of the feet or legs began increasing among U.S. adults with diabetes, while rates of end-stage renal disease, stroke, and acute myocardial infarction plateaued after 2010

These trends highlight the urgent need for interventions and strategies that safely resume progress in diabetes risk-factor control

Learn More – Primary Sources:

Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACC/AHA Blood Pressure Treatment Guideline: Lifestyle Modification and Drug Therapy
ACC/AHA Multisociety Guideline: Cholesterol Assessment and Primary ASCVD Prevention
Treating Type 2 Diabetes
Does Automated Insulin Dosing Guidance Optimize Management in Patients with Type 2 Diabetes?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site